Oesophageal cancer is not as well known as some other forms of cancer, but 1,470 Australians lose their lives to it each year. Only 22% of people diagnosed with oesophageal cancer live longer than five years.
This form of cancer is difficult to screen for or diagnose at an early stage, because the symptoms can be subtle or there can be none at all. Oesophageal cancer survivor Geoff Parnell says that being aware of the symptoms and taking care of your health are key to addressing this disease in the community.
The GI Cancer Institute is currently conducting four clinical trials offering new treatments to people with oesophageal cancer:
The purpose of this study is to investigate the effects of the addition of stereotactic body radiotherapy to treatment with nivolumab in people with oesophageal cancer that has spread to another area of the body (metastasised).
The purpose of this study is to assess the safety of adding the drug avelumab to chemo-radiation before surgery for people with oesophageal or gastro-oesophageal cancer.
The purpose of TOPGEAR is to investigate the benefit of adding radiation (chemoradiotherapy) to chemotherapy and surgery to treat and improve the overall survival in patients undergoing surgery.
The purpose of INTEGRATE II is to determine whether Regorafenib is effective in prolonging survival in patients with Advanced Gastro-Oesophageal Carcinoma (AGOC).
By being aware of the symptoms and risks of oesophageal cancer, you can be in control of reducing your own risk. Checking in with your general practitioner if you notice any symptoms or have concerns is a good way of taking care of yourself.